Takeda submits IBD drug candidate for FDA approval

06/25/2013 | PharmaTimes (U.K.)

Takeda Pharmaceutical has filed a biologics license application with the FDA for approval to use its experimental monoclonal antibody drug vedolizumab as a treatment for moderately to severely active Crohn's disease and ulcerative colitis. The application was based on data from four late-stage international trials involving 2,700 patients.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD